Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Divergent SARS CoV-2 Omicron-specific T- and B-cell responses in COVID-19 vaccine recipients

Corine H. GeurtsvanKessel, Daryl Geers, Katharina S. Schmitz, Anna Z. Mykytyn, Mart M Lamers, Susanne Bogers, Lennert Gommers, Roos S.G. Sablerolles, Nella N. Nieuwkoop, Laurine C. Rijsbergen, Laura L.A. van Dijk, Janet de Wilde, Kimberley Alblas, Tim I. Breugem, Bart J.A. Rijnders, Herbert de Jager, Daniela Weiskopf, P. Hugo M. van der Kuy, Alessandro Sette, Marion P.G. Koopmans, Alba Grifoni, Bart L. Haagmans, View ORCID ProfileRory D. de Vries
doi: https://doi.org/10.1101/2021.12.27.21268416
Corine H. GeurtsvanKessel
1Department of Viroscience, Erasmus MC, Rotterdam, the Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: c.geurtsvankessel@erasmusmc.nl b.haagmans@erasmusmc.nl r.d.devries@erasmusmc.nl
Daryl Geers
1Department of Viroscience, Erasmus MC, Rotterdam, the Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katharina S. Schmitz
1Department of Viroscience, Erasmus MC, Rotterdam, the Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna Z. Mykytyn
1Department of Viroscience, Erasmus MC, Rotterdam, the Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mart M Lamers
1Department of Viroscience, Erasmus MC, Rotterdam, the Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susanne Bogers
1Department of Viroscience, Erasmus MC, Rotterdam, the Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lennert Gommers
1Department of Viroscience, Erasmus MC, Rotterdam, the Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roos S.G. Sablerolles
2Department of Hospital Pharmacy, Erasmus MC, Rotterdam, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nella N. Nieuwkoop
1Department of Viroscience, Erasmus MC, Rotterdam, the Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laurine C. Rijsbergen
1Department of Viroscience, Erasmus MC, Rotterdam, the Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laura L.A. van Dijk
1Department of Viroscience, Erasmus MC, Rotterdam, the Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Janet de Wilde
1Department of Viroscience, Erasmus MC, Rotterdam, the Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kimberley Alblas
1Department of Viroscience, Erasmus MC, Rotterdam, the Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tim I. Breugem
1Department of Viroscience, Erasmus MC, Rotterdam, the Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bart J.A. Rijnders
3Department of Medical Microbiology and Infectious Diseases, Erasmus MC, Rotterdam, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Herbert de Jager
4Department of Occupational Health Services, Erasmus MC, Rotterdam, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniela Weiskopf
5Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P. Hugo M. van der Kuy
2Department of Hospital Pharmacy, Erasmus MC, Rotterdam, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alessandro Sette
5Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037, USA
6Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego (UCSD), La Jolla, CA 92037, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marion P.G. Koopmans
1Department of Viroscience, Erasmus MC, Rotterdam, the Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alba Grifoni
5Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bart L. Haagmans
1Department of Viroscience, Erasmus MC, Rotterdam, the Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: c.geurtsvankessel@erasmusmc.nl b.haagmans@erasmusmc.nl r.d.devries@erasmusmc.nl
Rory D. de Vries
1Department of Viroscience, Erasmus MC, Rotterdam, the Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Rory D. de Vries
  • For correspondence: c.geurtsvankessel@erasmusmc.nl b.haagmans@erasmusmc.nl r.d.devries@erasmusmc.nl
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

The severe acute respiratory distress syndrome coronavirus-2 (SARS-CoV-2) Omicron variant (B.1.1.529) is spreading rapidly, even in vaccinated individuals, raising concerns about immune escape. Here, we studied neutralizing antibodies and T-cell responses to SARS-CoV-2 D614G (wildtype, WT), and the B.1.351 (Beta), B.1.617.2 (Delta), and B.1.1.529 (Omicron) variants of concern (VOC) in a cohort of 60 health care workers (HCW) after immunization with ChAdOx-1 S, Ad26.COV2.S, mRNA-1273 or BNT162b2. High binding antibody levels against WT SARS-CoV-2 spike (S) were detected 28 days after vaccination with both mRNA vaccines (mRNA-1273 or BNT162b2), which significantly decreased after 6 months. In contrast, antibody levels were lower after Ad26.COV2.S vaccination but did not wane. Neutralization assays with authentic virus showed consistent cross-neutralization of the Beta and Delta variants in study participants, but Omicron-specific responses were significantly lower or absent (up to a 34-fold decrease compared to D614G). Notably, BNT162b2 booster vaccination after either two mRNA-1273 immunizations or Ad26.COV.2 priming partially restored neutralization of the Omicron variant, but responses were still up to-17-fold decreased compared to D614G. CD4+ T-cell responses were detected up to 6 months after all vaccination regimens; S-specific T-cell responses were highest after mRNA-1273 vaccination. No significant differences were detected between D614G- and variant-specific T-cell responses, including Omicron, indicating minimal escape at the T-cell level. This study shows that vaccinated individuals retain T-cell immunity to the SARS-CoV-2 Omicron variant, potentially balancing the lack of neutralizing antibodies in preventing or limiting severe COVID-19. Booster vaccinations may be needed to further restore Omicron cross-neutralization by antibodies.

Competing Interest Statement

A.S. is a consultant for Gritstone Bio, Flow Pharma, Arcturus Therapeutics, ImmunoScape, CellCarta, Avalia, Moderna, Fortress and Repertoire. L.J.I. has filed for patent protection for various aspects of T cell epitope and vaccine design work.

Funding Statement

This work was financially supported by the Netherlands Organization for Health Research and Development (ZONMW) grant agreement 10150062010008 to B.L.H. and grant agreement 10430072110001 to R.D.d.V., C.G.v.K., H.v.d.K and R.S., the Health∼Holland grants EMCLHS20017 to D.G., L.G., and R.D.d.V. and grant LSHM19136 to B.L.H and the European Unions Horizon 2020 research and innovation program under grant no. 101003589 (RECoVER: M.P.G.K.). B.L.H is supported by the NIH/NIAID Centers of Excellence for Influenza Research and Response (CEIRR) under contract 75N93021C00014-Icahn School of Medicine at Mt. Sinai. This project has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N93021C00016 to A.S. and Contract No. 75N9301900065 to A.S, D.W.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Samples from three different trials (HCW, ConCOVID, and SWITCH) were analysed in the scope of this study. The HCW study was approved by the institutional review board of the Erasmus MC (medical ethical committee, MEC-2020-0264). The ConCOVID trial was also approved by the institutional review board of the Erasmus MC (MEC 2020-0228). The study was registered at clinicaltrials.gov (NCT04342182). The SWITCH trial was approved by the institutional review board of the Erasmus MC (MEC 2021-0132) and local review boards of participating centres. The study was registered at clinicaltrials.gov (NCT04927936). All studies adhere to the principles of the Declaration of Helsinki, and written informed consent was obtained from every participant, patient or legal representative.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present study are available upon reasonable request to the authors.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted December 29, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Divergent SARS CoV-2 Omicron-specific T- and B-cell responses in COVID-19 vaccine recipients
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Divergent SARS CoV-2 Omicron-specific T- and B-cell responses in COVID-19 vaccine recipients
Corine H. GeurtsvanKessel, Daryl Geers, Katharina S. Schmitz, Anna Z. Mykytyn, Mart M Lamers, Susanne Bogers, Lennert Gommers, Roos S.G. Sablerolles, Nella N. Nieuwkoop, Laurine C. Rijsbergen, Laura L.A. van Dijk, Janet de Wilde, Kimberley Alblas, Tim I. Breugem, Bart J.A. Rijnders, Herbert de Jager, Daniela Weiskopf, P. Hugo M. van der Kuy, Alessandro Sette, Marion P.G. Koopmans, Alba Grifoni, Bart L. Haagmans, Rory D. de Vries
medRxiv 2021.12.27.21268416; doi: https://doi.org/10.1101/2021.12.27.21268416
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Divergent SARS CoV-2 Omicron-specific T- and B-cell responses in COVID-19 vaccine recipients
Corine H. GeurtsvanKessel, Daryl Geers, Katharina S. Schmitz, Anna Z. Mykytyn, Mart M Lamers, Susanne Bogers, Lennert Gommers, Roos S.G. Sablerolles, Nella N. Nieuwkoop, Laurine C. Rijsbergen, Laura L.A. van Dijk, Janet de Wilde, Kimberley Alblas, Tim I. Breugem, Bart J.A. Rijnders, Herbert de Jager, Daniela Weiskopf, P. Hugo M. van der Kuy, Alessandro Sette, Marion P.G. Koopmans, Alba Grifoni, Bart L. Haagmans, Rory D. de Vries
medRxiv 2021.12.27.21268416; doi: https://doi.org/10.1101/2021.12.27.21268416

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (216)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1099)
  • Dentistry and Oral Medicine (196)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (502)
  • Epidemiology (9781)
  • Forensic Medicine (5)
  • Gastroenterology (481)
  • Genetic and Genomic Medicine (2317)
  • Geriatric Medicine (223)
  • Health Economics (462)
  • Health Informatics (1563)
  • Health Policy (737)
  • Health Systems and Quality Improvement (605)
  • Hematology (238)
  • HIV/AIDS (506)
  • Infectious Diseases (except HIV/AIDS) (11655)
  • Intensive Care and Critical Care Medicine (617)
  • Medical Education (239)
  • Medical Ethics (67)
  • Nephrology (258)
  • Neurology (2146)
  • Nursing (134)
  • Nutrition (338)
  • Obstetrics and Gynecology (427)
  • Occupational and Environmental Health (518)
  • Oncology (1183)
  • Ophthalmology (365)
  • Orthopedics (128)
  • Otolaryngology (220)
  • Pain Medicine (147)
  • Palliative Medicine (50)
  • Pathology (312)
  • Pediatrics (698)
  • Pharmacology and Therapeutics (302)
  • Primary Care Research (267)
  • Psychiatry and Clinical Psychology (2187)
  • Public and Global Health (4672)
  • Radiology and Imaging (781)
  • Rehabilitation Medicine and Physical Therapy (457)
  • Respiratory Medicine (624)
  • Rheumatology (274)
  • Sexual and Reproductive Health (226)
  • Sports Medicine (210)
  • Surgery (252)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)